Welcome to our dedicated page for Pure Bioscience news (Ticker: PURE), a resource for investors and traders seeking the latest updates and insights on Pure Bioscience stock.
PURE Bioscience develops and commercializes antimicrobial products built on its patented silver dihydrogen citrate (SDC) technology. Company updates center on SDC-based food safety and sanitation applications for food and beverage manufacturing, produce processing, transportation sanitation, and janitorial and consumer cleaning channels.
Recurring news includes fiscal financial results, net product sales trends, distribution partner activity, and product applications such as PURE Control for direct food-contact use and PURE Hard Surface for dairy and beverage membrane treatment. PURE also reports governance and leadership changes tied to its commercial operations and regulatory affairs functions.
PURE Bioscience reported its fiscal Q3 2024 financial results, highlighting a net product sales increase to $440,000 from $406,000 YoY, and a reduced net loss of $857,000 from $876,000 YoY. For the nine months ending April 30, 2024, net product sales were up to $1,483,000 from $1,269,000 YoY, with net loss decreasing to $2,594,000 from $2,929,000 YoY. The company is transitioning from a direct sales model to a distributor model, developing new pricing agreements, boosting social media engagement by 167%, and increasing followers by 70%. They continue to participate in trade shows and expand R&D efforts, focusing on food safety and environmental sustainability in industries like dairy and animal health.
PURE Bioscience, Inc. appointed Darin Zehr to its Board of Directors, effective May 1, 2024. Zehr, with extensive experience in the food industry, joins as an independent director and will serve on PURE's Audit and Compensation Committees. He previously worked at Kraft Foods for 22 years and is currently the General Manager of Commercial Food Sanitation Zehr holds a Bachelor of Science degree in Chemistry and brings valuable insights to PURE's Board.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PURE Bioscience, Inc. (OTCQB: PURE) reported its Q2 and six-month results ended January 31, 2023. Net product sales decreased to $396,000 in Q2 from $415,000 in 2022, with a net loss of $1,060,000 compared to $702,000 in the same quarter last year. For the six months, sales totaled $863,000, down from $912,000, with losses rising to $2,053,000 versus $1,498,000 year-over-year. The company appointed Robert Bartlett as the new CEO on March 15, 2023, aiming to enhance revenue and redirect sales strategies.
PURE Bioscience reported its fiscal first quarter results for the period ending October 31, 2022, with net product sales of $467,000, down from $497,000 in the previous year. The company faced a net loss of $993,000, compared to $796,000 year-over-year. Despite these challenges, substantial adoption of the SDC-based antimicrobial in potato, snack food, and bakery sectors is noted, alongside growth in the dairy industry. New regional managers have been hired to enhance sales efforts across multiple industries. CEO Tom Y. Lee highlighted positive momentum and industry acceptance.
Hydrite has secured a multi-year exclusive distribution agreement with PURE Bioscience, Inc. for its PURE® Hard Surface disinfectant in the dairy and plant-based protein markets. This SDC-based product is designed to effectively eliminate foodborne pathogens. With Hydrite's established presence in dairy processing, the partnership aims to enhance food safety and sanitation solutions. The agreement positions PURE® Hard Surface as an essential tool for dairy and plant-based protein facilities, allowing for improved sanitation practices.